TITLE

Recombinant human activated protein C in severe sepsis

AUTHOR(S)
Mann, Henry J.
PUB. DATE
February 2002
SOURCE
American Journal of Health-System Pharmacy;2/15/2002, Vol. 59 Issue 4, pS19
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Protein C, a naturally occurring vitamin K-dependent serine protease in the blood, remains inactive until exposed to the thrombin-thrombomodulin complex. This change between the inactive and active forms occurs constantly in humans and serves to balance the coagulation cascade. APC functions in concert with protein S as an anticoagulant, a fibrinolytic agent, and an antiinflammatory agent. In response to serious infection, a procoagulant process is activated leading to thrombin and fibrin deposition in small vessels that results in decreased blood flow, decreased oxygen delivery, and organ failure. The body's natural defense during severe sepsis is to activate protein C through the thrombinthrombomodulin complex in an attempt to restore the imbalance of the hemostatic systems. However, APC has a short half-life, and the pool of circulating protein C is rapidly depleted in severe sepsis. Low protein C levels have been correlated with poor outcome in patients with severe sepsis and in animal models. These observations led to a Phase III safety and efficacy trial of drotrecogin alfa (activated) that demonstrated a significant improvement in mortality compared with placebo (24.7% versus 30.8%). This 6.1% absolute difference in mortality translates to a 19.4% reduction in relative risk of death in the treated patients. The proper use of drotrecogin alfa (activated) will require careful consideration of appropriate patients to treat and further studies in patient populations that were excluded from the Phase III trial, as well as possible modification of dosing schemes on the basis of patient response.
ACCESSION #
6504629

 

Related Articles

  • Fresh from the pipeline: Drotrecogin alpha (activated). Lebbos, John; Bradsher, Julia; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Jan2003, Vol. 2 Issue 1, p13 

    In November 2001, drotrecogin alpha (activated) (Xigris) became the first drug to be approved by the FDA for the treatment of severe sepsis, a systemic response to infection that kills an estimated 500,000 people each year. Xigris was widely anticipated to be a blockbuster, but it has not yet...

  • Managing high-cost biotechnology products. Wong, Dorothy H.; Yang, Peggy // American Journal of Health-System Pharmacy;6/15/2003, Vol. 60 Issue 12, p1213 

    Offers ways to ensure the appropriate use of Drotrecogin alfa, a recombinant human activated protein C with U.S. Food and Drug Administration-approved labeling for use in the treatment of severe sepsis in adult. Medication-related issues; Criteria for use; Medication-use evaluation to track...

  • P & T PORTFOLIO.  // Drug Topics;2/18/2002, Vol. 146 Issue 4, p16 

    Evaluates the recombinant form of human protein C, Drotrecogin alfa for reducing mortality in adult patients with severe sepsis. Efficacy of the drug; Pharmacology; Warnings related to use.

  • Drotrecogin Alfa (Activated): A Viewpoint by Marcel Levi. Levi, M. // Drugs;2002, Vol. 62 Issue 4, p631 

    Examines the therapeutic use of protein C in the treatment of sepsis. Role of microvascular thrombosis in organ failure and mortality in patients with sepsis; Beneficial effect of activated protein C; Strategies to reduce mortality from sepsis.

  • Finally a treatment for sepsis? Saunders, Carol S. // Patient Care;9/30/2000, Vol. 34 Issue 18, p12 

    Deals with the results of a clinical trial investigating recombinant human activated protein C for the treatment of severe sepsis. Stoppage of the third phase of the trial; Proposed product name.

  • Drotrecogin alfa (activated). Caron, Michael R.; Kuti, Joseph L.; Quintiliani, Richard; White, C. Michael // Formulary;Nov2001, Vol. 36 Issue 11, p784 

    Drotrecogin alfa (activated), a recombinantly produced preparation of human activated protein C, reduces the inflammatory, procoagulant, and antifibrinolytic host response to infection. At press time, an FDA advisory committee was split over whether to recommend it for approval for treating...

  • World's Largest Severe Sepsis Clinical Trial.  // BioPharm International;Nov2002, Vol. 15 Issue 11, p14 

    Reports on the approval received by Eli Lilly's drug Xigris, a recombinant form of human protein C, by the U.S. Food and Drug Administration for reducing mortality in severe sepsis adults at high risk of death. Launch of a severe sepsis clinical trial which will study the effectiveness of...

  • Advances in Sepsis Therapy. Gl├╝ck, Thomas; Opal, Steven M. // Drugs;2004, Vol. 64 Issue 8, p837 

    During the past 3 years new insights have been gained into the fundamental elements that underlie the pathogenesis of sepsis, and after years of frustrating failures, progress in the basic understanding of sepsis has translated into successful new therapies. These new treatment strategies have...

  • Lilly Hopes Sepsis Drug Will Cushion Prozac Expiry. Jarvis, Lisa // Chemical Market Reporter;11/27/2000, Vol. 258 Issue 22, p5 

    Reports on the development of a recombinant human activated protein C drug for the treatment of sepsis, manufactured by Eli Lilly & Co. Estimated number of people in the United States who suffered from sepsis annually; Benefits given by the drug to the company.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics